Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
20.75
-0.42 (-1.98%)
At close: Jun 27, 2025, 11:12 AM
-1.98% (1D)
| Bid | 20.73 |
| Market Cap | 1.38B |
| Revenue (ttm) | 7.56M |
| Net Income (ttm) | -178.85M |
| EPS (ttm) | -2.7 |
| PE Ratio (ttm) | -7.68 |
| Forward PE | -5.35 |
| Analyst | Buy |
| Ask | 20.79 |
| Volume | 309,217 |
| Avg. Volume (20D) | 952,706 |
| Open | 21.09 |
| Previous Close | 21.17 |
| Day's Range | 20.73 - 21.44 |
| 52-Week Range | 14.40 - 47.00 |
| Beta | 1.14 |
About CLDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Celldex Therapeutics Inc. is scheduled to release its earnings on Aug 7, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
-12.06%
Celldex Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
11 months ago
-8.45%
Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.
